Fortress Biotech (NASDAQ:FBIO) is up 62% premarket on average volume in lockstep with the rally in subsidiary Mustang Bio (NASDAQ:MBIO) related to positive data from a clinical trial evaluating its lentiviral gene therapy in ten infants with bubble boy disease (lack of immunity).
Thinly traded MBIO is up 255% premarket on increased volume, albeit on turnover of only 56K shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.